Leerink raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $11 from $9 and keeps a Market Perform rating on the shares after the FDA granted accelerated approval for Kresladi for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I. Leerink increased probability of success from 85% to 100%, pushed first infusion to 2027 and lowered discount rate to 10%, the firm told investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- PRV reception could net Rocket $100M-$200M, says LifeSci Capital
- Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
- Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
- Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
- Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating